Get the Stockscreener App
37.34
1.27%
0.47
Rapport Therapeutics Inc stock is traded at $37.34, with a volume of 355.44K.
It is up +1.27% in the last 24 hours and up +6.14% over the past month.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
See More
Previous Close:
$36.87
Open:
$37.75
24h Volume:
355.44K
Relative Volume:
1.09
Market Cap:
$1.79B
Revenue:
-
Net Income/Loss:
$-107.28M
P/E Ratio:
-14.34
EPS:
-2.6031
Net Cash Flow:
$-80.71M
1W Performance:
+6.05%
1M Performance:
+6.14%
6M Performance:
+25.98%
1Y Performance:
+238.53%
1-Day Range:
$36.46
$38.12
1-Week Range:
$35.61
$39.98
52-Week Range:
$10.51
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
37.34 | 1.79B | 0 | -107.28M | -80.71M | -2.6031 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Feb-02-26 | Initiated | Wells Fargo | Overweight |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-16-25 | Initiated | Truist | Buy |
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
View All
Rapport Therapeutics Inc Stock (RAPP) Latest News
Rapport Therapeutics Inc (RAPP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rapport Therapeutics Inc (RAPP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rapport Therapeutics Inc (RAPP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rapport Therapeutics Inc (RAPP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rapport Therapeutics Inc (RAPP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rapport Therapeutics Inc (RAPP) Institutional Confidence - TradingKey
Rapport Therapeutics Inc (RAPP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now? - Insider Monkey
Rapport Therapeutics Inc (RAPP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rapport Therapeutics (RAPP) director receives 15,200 stock options grant - Stock Titan
[Form 4] Rapport Therapeutics, Inc. Insider Trading Activity - Stock Titan
Rapport Therapeutics (RAPP) director receives 15,200-share stock option grant - Stock Titan
Rapport Therapeutics (RAPP) director granted 15,200 stock options at $35.21 - Stock Titan
Rapport Therapeutics Holds 2026 Annual Shareholder Meeting - TipRanks
Rapport Therapeutics (RAPP) holders elect Class II board, ratify PwC - Stock Titan
Goldman Sachs Group Inc. Buys 579,903 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Precision Trading with Rapport Therapeutics Inc. (RAPP) Risk Zones - Stock Traders Daily
Rapport Therapeutics (RAPP) Edges Higher Amid Tight Trading RangePut Flow Alert - newsline.com
Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative? - Yahoo Finance
Wall Street Firms Raise Rapport Therapeutics Price Targets - sekbernews.id
BTIG and Truist Raise Price Targets for Rapport Therapeutics - HarianBasis.co
BTIG Raises its Price Target on Rapport Therapeutics (RAPP) - Insider Monkey
RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy - TipRanks
5 Stocks That Have the Potential to Rise 1000% - Insider Monkey
Number of shareholders of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
BTIG Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Citizens reiterates Rapport Therapeutics stock rating on competitor trial data - Investing.com
Citizens reiterates Rapport Therapeutics stock rating on competitor trial data By Investing.com - Investing.com Canada
Rapport Therapeutics (RAPP) Q1 2026 Earnings: Narrower Loss Beats Estimates; Stock Holds Steady - newsline.com
Technical Reactions to RAPP Trends in Macro Strategies - Stock Traders Daily
RAPP Q1 2026 Earnings: Narrower Loss Beats Street Estimates as Pre-Revenue Biotech Advances Pipeline - newsline.com
Rapport Therapeutics (RAPP) Holds Steady as Minor Decline Tests Key Support LevelsKeltner Channel - newsline.com
Third Rock sells 836,136 RAPP shares across April–May 2026 (RAPP) - Stock Titan
Rapport Therapeutics Inc. (RAPP) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock GainProduct Revenue Analysis - Newser
RAPP Should I Buy - Intellectia AI
Rapport Therapeutics (RAPP) Gains 2.7% as Price Approaches Key Resistance LevelValue Factor - Newser
RAPP Maintains Buy Rating -- Price Target Raised to $65.00 by BT - GuruFocus
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Rapport Therapeutics to Participate in the Jefferies Global - GlobeNewswire
RAPP Assumes Buy Rating with Price Target Raised to $56.00 by Tr - GuruFocus
Truist Financial Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Rapport Therapeutics (RAPP) Stock Today: Drops -1.71%, Key Support at $32.85 2026-05-19Index Put Call - newsline.com
Rapport Therapeutics Inc (RAPP) - MSN
Truist assumes Rapport Therapeutics stock with buy on epilepsy drug By Investing.com - Investing.com Canada
Truist Financial Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $56 - Moomoo
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside - TipRanks
Trading the Move, Not the Narrative: (RAPP) Edition - Stock Traders Daily
Will Narrowing Losses And Per Share Improvement Reframe Rapport Therapeutics' (RAPP) Investment Narrative? - simplywall.st
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
Vanguard Group Inc. Acquires 191,219 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Third Rock Ventures v sells $5.38m in Rapport Therapeutics stock By Investing.com - Investing.com South Africa
Rapport Therapeutics Inc Stock (RAPP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):